SAIC Inc. (NYSE: SAI) has been awarded a contract by the National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health, to provide preclinical services for the development of biopharmaceutical products for infectious diseases.
SAIC will provide a suite of product development services, including feasibility assessments, cGMP manufacturing, process development and regulatory activities.
Funded at $1.9 million at the end of fiscal year 2011, the contract could be worth up to $102 million over the ten year performance period.
“SAIC is pleased to assist and support NIAID with the development of biopharmaceutical products that will help prevent harmful diseases and improve human health, ” said Steve Comber, SAIC senior vice president and business unit general manager.